Indication
Details coming soon
Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 2 Diabetes Mellitus, Adverse cardiovascular events Age: Adults |
Dose: Subcutaneous – 0.25 mg Frequency: once weekly Duration: 4 weeks Note: Intended for treatment initiation and is not effective for glycemic control. |
|
Indication: Type 2 Diabetes Mellitus, Adverse cardiovascular events Age: Adults |
Dose: Subcutaneous – 0.5 mg Frequency: once weekly Note: Increase to this dosage after the initial 4 weeks at 0.25 mg. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: less than 18 years |
Dose: Not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not mentioned Note: No dosage adjustment required |
Administration
- Inject once weekly
- Same day each week
Side Effect
- Nausea (15.8-20.3%)
- Documented symptomatic hypoglycemia, adjunctive therapy [≤70 mg/dL glucose threshold] (16.7-29.8%)
- Severe or symptomatic hypoglycemia, adjunctive therapy [≤56 mg/dL glucose threshold] (8.3-10.7%)
- Vomiting (5-9.2%)
- Diarrhea (8.5-8.8%)
- Abdominal pain (5.7-7.3%)
- Constipation (3.1-5%)
- Dyspepsia (2.7-3.5%)
- Eructation (1.1-2.7%)
- Documented symptomatic hypoglycemia, monotherapy [≤70 mg/dL glucose threshold] (1.6-3.8%)
- Flatulence (0.4-1.5%)
- Gastroesophageal reflux disease (1.5-1.9%)
- Gastritis (0.4-0.8%)
- Cholelithiasis (0.4%)
- Fatigue (More than 0.4%)
- Dysgeusia (More than 0.4%)
- Dizziness (More than 0.4%)
- Injection site reaction (0.2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Insulin, sulfonylureas
|
May increase the risk of hypoglycemia
|
|
Oral medications
|
May impact absorption of oral medications
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Personal/Family History of MTC
|
Risk of thyroid cancer
|
|
Multiple Endocrine Neoplasia Type 2
|
Risk of endocrine tumors
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.